Find in Library

Jinling Bi, Haiyuan Liu, Yong Huang Department of Oncology, The Second People’s Hospital of He Fei, He Fei, An Hui, People’s Republic of China Abstract: The aim of this study was to explore the effect of apatinib in the treatment of metastatic renal cell carcinoma (mRCC) and related adverse events. A case of mRCC was reported which recurred after surgery and roferon treatment. The patient was treated with apatinib at a dose of 500 mg orally, twice daily, 28 days/cycle. The metastatic lesions improved based on computed tomography after apatinib administration in the fourth and eighth month. The progression-free survival of the patient had increased almost to 8 months. The patient showed a good tolerance with only an adverse effect of mild-to-moderate hand-foot syndrome which was managed well. Apatinib is an option for mRCC after previous treatment. However, more and larger trials are still needed. Keywords: metastatic renal cell carcinoma, apatinib, sunitinib, sorafenib, vascular endothelial growth factor receptor